Literature DB >> 23000645

Risk and prognostic factors for acute GVHD based on NIH consensus criteria.

S-E Lee1, B-S Cho, J-H Kim, J-H Yoon, S-H Shin, S-A Yahng, K-S Eom, Y-J Kim, H-J Kim, S Lee, C-K Min, S-G Cho, D-W Kim, J-W Lee, W-S Min, C-W Park.   

Abstract

To investigate the risk factors for acute GVHD (aGVHD), based on NIH consensus criteria (NCC), we evaluated 775 patients who underwent allogeneic transplantation. Of them, 346 patients developed aGVHD by NCC, in whom we also analyzed factors affecting aGVHD-specific survival. The cumulative incidence of aGVHD was 44.7%, consisting of classic aGVHD (n=320) and late-onset (n=26). Multivariate analyses revealed that younger age (P=0.015), unrelated donors (P=0.004) and acute leukemia compared with other hematologic malignancies (P=0.005) were significant risk factors for aGVHD, whereas PBSCs showed no association (P=0.720). Multivariate analyses, with only aGVHD patients, revealed that late-onset aGVHD had superior aGVHD-specific survival to classic aGVHD (P=0.044), and identified the association of visceral organ involvement (P=0.002), severity of aGVHD at onset (P=0.035) and advanced disease status (P<0.001) with inferior aGVHD-specific survival. In conclusion, this study demonstrates the risk and prognostic factors for aGVHD by NCC with some differences with the previous reports that were based on old criteria. The difference in the risk factors according to different criteria will give insights about the pathophysiology of GVHD. The better prognosis of late-onset aGVHD than of classic aGVHD raises the necessity for prospective trials with a large cohort focusing on the onset time.

Entities:  

Mesh:

Year:  2012        PMID: 23000645     DOI: 10.1038/bmt.2012.187

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  20 in total

Review 1.  Acute graft-versus-host disease of the gut: considerations for the gastroenterologist.

Authors:  Steven Naymagon; Leonard Naymagon; Serre-Yu Wong; Huaibin Mabel Ko; Anne Renteria; John Levine; Jean-Frederic Colombel; James Ferrara
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-09-27       Impact factor: 46.802

2.  Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapse.

Authors:  Andrew Kent; Sumithira Vasu; Derek Schatz; Natalie Monson; Steven Devine; Clayton Smith; Jonathan A Gutman; Daniel A Pollyea
Journal:  Blood Adv       Date:  2020-07-14

3.  Extracorporeal photopheresis increases neutrophilic myeloid-derived suppressor cells in patients with GvHD.

Authors:  N Rieber; I Wecker; D Neri; K Fuchs; I Schäfer; A Brand; M Pfeiffer; P Lang; W Bethge; O Amon; R Handgretinger; D Hartl
Journal:  Bone Marrow Transplant       Date:  2014-01-27       Impact factor: 5.483

4.  STAT3 Expression in Host Myeloid Cells Controls Graft-versus-Host Disease Severity.

Authors:  Evelyn C Nieves; Tomomi Toubai; Daniel C Peltier; Katherine Oravecz-Wilson; Chen Liu; Hiroya Tamaki; Yaping Sun; Pavan Reddy
Journal:  Biol Blood Marrow Transplant       Date:  2017-07-08       Impact factor: 5.742

Review 5.  The Role of Biomarkers in the Diagnosis and Risk Stratification of Acute Graft-versus-Host Disease: A Systematic Review.

Authors:  Alaa M Ali; John F DiPersio; Mark A Schroeder
Journal:  Biol Blood Marrow Transplant       Date:  2016-05-05       Impact factor: 5.742

6.  A panel of 4 biomarkers for the early diagnosis and therapeutic efficacy of aGVHD.

Authors:  Xiaoping Li; Ting Chen; Qiangguo Gao; Wei Zhang; Yunshuo Xiao; Wen Zhu; Lingyu Zeng; Zhenyu Li; Shijie Yang; Rui Wang; Xiaoqi Wang; Yimei Feng; Xi Zhang
Journal:  JCI Insight       Date:  2019-08-22

7.  Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors.

Authors:  Shernan G Holtan; Nandita Khera; John E Levine; Xiaoyu Chai; Barry Storer; Hien D Liu; Yoshihiro Inamoto; George L Chen; Sebastian Mayer; Mukta Arora; Jeanne Palmer; Mary E D Flowers; Corey S Cutler; Alexander Lukez; Sally Arai; Aleksandr Lazaryan; Laura F Newell; Christa Krupski; Madan H Jagasia; Iskra Pusic; William Wood; Anne S Renteria; Gregory Yanik; William J Hogan; Elizabeth Hexner; Francis Ayuk; Ernst Holler; Phandee Watanaboonyongcharoen; Yvonne A Efebera; James L M Ferrara; Angela Panoskaltsis-Mortari; Daniel Weisdorf; Stephanie J Lee; Joseph Pidala
Journal:  Blood       Date:  2016-09-13       Impact factor: 22.113

8.  Drug-induced liver injury after allogeneic bone marrow transplantation.

Authors:  Takayoshi Tachibana; Akito Nozaki; Makiko Enaka; Eri Yamamoto; Rika Kawasaki; Hideyuki Koharazawa; Maki Hagihara; Daisuke Ishibashi; Yuki Nakajima; Hideyuki Kuwabara; Naoto Tomita; Yoshiaki Ishigatsubo; Shin Fujisawa
Journal:  Int J Hematol       Date:  2013-09-15       Impact factor: 2.490

9.  Establishing a standardized system for review and adjudication of chronic graft-vs-host disease data in accordance with the National Institutes Consensus criteria.

Authors:  Djamilia Dierov; Nicholas Webb; Samira Fatmi; Chamberlain Nwanne; Cristi Ciolino; Kara Mosesso; Jimmy Nieves; Miguel-Angel Perales; Susan E Prockop; Doris M Ponce
Journal:  Adv Cell Gene Ther       Date:  2019-05-02

10.  Single-Agent Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis after Human Leukocyte Antigen-Matched Related Bone Marrow Transplantation for Pediatric and Young Adult Patients with Hematologic Malignancies.

Authors:  Elad Jacoby; Allen Chen; David M Loeb; Christopher J Gamper; Elias Zambidis; Nicolas J Llosa; Jeffrey Huo; Kenneth R Cooke; Rick Jones; Ephraim Fuchs; Leo Luznik; Heather J Symons
Journal:  Biol Blood Marrow Transplant       Date:  2015-09-04       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.